Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
ImmunoGen
ImmunoGen is a clinical-stage biotechnology company that develops antibody-based anticancer therapeutics.
Sector
Subsector
Keywords
Location
total rounds
total raised
Advanced Proteome Therapeutics
Advanced Proteome Therapeutics is a biotech company that develops novel therapeutics for cancer treatment.
Sector
Subsector
Keywords
Location
total rounds
total raised
Apeiron Biologics
Apeiron Biologics is a biotech company focused on developing novel cancer immunotherapies.
Sector
Subsector
Keywords
Location
total rounds
total raised
Abcuro
Abcuro develops immunomodulatory therapeutics for treating autoimmunity and cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds3
Number of Funding Rounds
Money Raised
Their latest funding was raised on 19.05.2021. Their latest investor 6 Dimensions Capital. Their latest round Debt Financing
Hercules Capital
Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, innovative venture capital-backed companies.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
ARCH Venture Partners
ARCH Venture Partners is a venture capital firm that specializes in investing in early-stage technology companies in the United States.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors11
Number of lead investors
Number of investors
6 Dimensions Capital
6 Dimensions Capital is a healthcare investment firm.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Kevin Heyeck
Magnetic Ventures
Magnetic Ventures invests in early stage companies at the intersection of life science and technology.
Sector
Subsector
Keywords
count Of Investments
count Of Exists
Life Sciences Fund Amsterdam
Life Sciences Fund Amsterdam is an investment firm in the life sciences sector.
Sector
Subsector
Keywords
Location
count Of Investments
Acquisitions2
Genuity Science acquired by HiberCell
acquirer
date
type
price
Genuity Science
Genuity Science provides genomics and data services to biopharma companies to improve patient health.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Biothera acquired by HiberCell
acquirer
date
type
Biothera
Biothera develops natural gluco polysaccharides that engage and direct innate immune systems.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders3
Julio Aguirre-Ghiso
Julio Aguirre-Ghiso is the Co-Founder at HiberCell.
current job
organization founded
Julio Aguirre-Ghiso
Ari Nowacek
Ari Nowacek, M.D, Ph.D. is a Principal with ARCH, joining the company as an Analyst in March 2015. Dr. Nowacek focuses on identifying and evaluating new life sciences technologies and also provides operating assistance to early-stage portfolio companies. Dr. Nowacek is a physician-scientist by training with over 20 peer-reviewed publications and greater than 400 citations in the areas of neuroscience, virology, and antiretroviral therapeutic development. His research has led to 3 issued and 2 pending patents for therapeutic and R&D applications. He holds a B.S. in Biology and a B.S. in Psychology from the University of Indiana-Bloomington where he graduated Magna Cum Laude and was elected to Phi Beta Kappa. He also holds an M.D. and Ph.D. from the University of Nebraska Medical Center and an M.B.A. from the University of Nebraska-Omaha. He subsequently completed a medical residency in pathology and post-doctoral research at The University of Chicago and Massachusetts General Hospital.
current job
Ari Nowacek
Alan Rigby
Alan Rigby is a passionate and innovative oncology leader with over 20 years of academic and industry experience in the area of data driven oncology drug discovery from concept to clinical candidate to genetically enabled first-in-man studies. Dr. Rigby is committed to leveraging patient material and data for use in the identification, stratification and development of ‘next generation’ cancer therapeutics for use in responder populations. This ‘commitment’ has resulted in clinically validated large and small molecule therapeutics for several cancer indications. Most recently, Alan led a prioritized and focused effort to translate ‘Natures Intracellular Biologic’ into transformative medicines for oncology and antibiotic resistance while chief scientific officer of Warp Drive Bio., a Cambridge based biotechnology company that was recently acquired. Alan joined Warp Drive Bio following a tenure as senior vice president and chief scientific officer at Synta Pharmaceuticals. While at Synta Alan led research and development efforts for Synta’s HSP90 clinical candidate, Ganetespib, as well as restructuring the preclinical small molecule drug conjugate platform. Prior to joining Synta, Dr. Rigby was vice president, global antibody drug conjugate biology, and head of external innovation for oncology research at the New York site for Eli Lilly and Company. Before launching his biotech/ pharmaceutical career Dr. Rigby was a National Institutes of Health (NIH) funded assistant professor and principal investigator at Beth Israel Deaconess Medical Center, Harvard Medical School. While at Harvard Medical School, he founded and directed the Drug Discovery and Target Validation Program within the Beth Israel Deaconess Medical Center. As a mentor and advisor Alan continues to work with numerous organizations to assemble and chair scientific conferences with a focus on translating innovative science and oncology-centric platforms into robust and durable clinically validated strategies. Alan Rigby is on the Editorial Advisory Board for Future Medicinal Chemistry, was North American Editor for Current Computer Aided Drug Discovery and has published more than 55 scientific papers, a book chapter and has 12 patents that have published or are pending. Alan holds an Honors BSc. in Biochemistry from the University of Western Ontario in London, Ontario, Canada and a Ph.D. in Biochemistry from the same University.
current job
organization founded
Alan Rigby
Employee Profiles12
Joseph Talamo
Senior Vice President and Chief Financial Officer
David Surguladze
Vice president preclinical pharmacology
Activity
Recent News9
The graph reveals the ratio (%) of positive news articles in a chosen time range